Randomized Phase III Trial Evaluating FOLFOX With or Without DOCETAXEL (TFOX) in 1st Line of Chemotherapy for Locally Advanced or Metastatic Esophageal Adenocarcinoma [ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES]
Latest Information Update: 07 Mar 2025
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms GASTFOX; GASTFOX-PRODIGE 51
Most Recent Events
- 05 Mar 2025 Status changed from active, no longer recruiting to completed.
- 05 Jul 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2025.
- 05 Jul 2024 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.